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Abstract
Aim: To determine the pharmacogenetics of platinum-based chemotherapy in Non Small Cell Lung Cancer (NSCLC)
patients.
Methods: Publications were selected from PubMed, Cochrane Library and ISI Web of Knowledge. A meta-analysis was
conducted to determine the association between genetic polymorphisms and platinum-based chemotherapy by checking
odds ratio (OR) and 95% confidence interval (CI).
Results: Data were extracted from 24 publications, which included 11 polymorphisms in 8 genes for meta-analysis. MDR1
C3435T (OR=1.97, 95% CI: 1.11–3.50, P=0.02), G2677A/T (OR=2.61, 95% CI: 1.44–4.74, P=0.002) and GSTP1 A313G
(OR=0.32, 95% CI: 0.17–0.58, P=0.0002) were significantly correlated with platinum-based chemotherapy in Asian NSCLC
patients.
Conclusion: Attention should be paid to MDR1 C3435T, G2677A/T and GSTP1 A313G for personalized chemotherapy
treatment for NSCLC patients in Asian population in the future.
Citation: Yin J-Y, Huang Q, Zhao Y-C, Zhou H-H, Liu Z-Q (2012) Meta-Analysis on Pharmacogenetics of Platinum-Based Chemotherapy in Non Small Cell Lung
Cancer (NSCLC) Patients. PLoS ONE 7(6): e38150. doi:10.1371/journal.pone.0038150
Editor: Srikumar P. Chellappan, H. Lee Moffitt Cancer Center & Research Institute, United States of America
Received February 15, 2012; Accepted May 1, 2012; Published June 26, 2012
Copyright:  2012 Yin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by National Natural Science Foundation of China (81173129) (Z.Q.L.), National High-Tech R&D Program of China (863Program)
(2009AA022703) (Z.Q.L. and J.Y.Y.), Specialized Research Fund for the Doctoral Program of Higher Education (20113420120006) (Q.H.) and Grants for Scientific
Research of BSKY (XJ201021) from Anhui Medical University (Q.H.). J.Y.Y. was supported in part by Scholarship Award for Excellent Doctoral Student granted by
the Ministry of Education of China. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: liuzhaoqian63@126.com
Introduction
Lung cancer is one of the most serious public health problems
around the globe. There are two major forms of lung cancer: small
cell lung cancer (SCLC) and non small cell lung cancer (NSCLC),
with the latter accounting for 85% of total cases [1]. Although
intensive effort has been made to improve the efficacy of lung
cancer therapy, the 5-year relative survival rate still remains
between 11% and 17% [2].
Platinum-based chemotherapy is one of the major therapeutic
methods for NSCLC, especially for advanced cancer. However, in
clinical practice, the chemotherapy response varies wildly among
individuals. Some patients respond to the chemotherapy, while
others confer intrinsic or acquired resistance. It is speculated that
some genetic polymorphisms may affect drug response, and there
are accumulating evidences to support this hypothesis [3–5].
Therefore, understanding the association between the polymor-
phisms and platinum response will be beneficial for individualized
chemotherapy. Although a number of studies investigated this
issue, there is no congruency for the relationship between genetic
polymorphisms and NSCLC platinum-based chemotherapy re-
sponse. Results from different studies are inconsistent with one
another. For example, Su et al. found excision repair cross-
complementing 1 (ERCC1) C354T was significantly associated
with drug response while other studies presented contradictory
results [6–8]. The same situation exists for GSTP1 A313G [9–11].
A recent review summarized the pharmacogenomics of platinum-
based chemotherapy in NSCLC [12]. However, a quantitative
evaluation is still lacking.
The aim of this study is to provide a comprehensive assessment
on the association between genetic polymorphisms and platinum-
based drug response in NSCLC. We collected all available
publications on pharmacogenetic studies of platinum-based
chemotherapy in NSCLC, and quantitatively studied them using
meta-analysis.
Materials and Methods
Literature search: A systematic literature search was performed
independently by two authors (J.Y.Y. and Q.H.) in three electronic
databases: PubMed database, Cochrane Library and ISI Web of
Knowledge. The identified articles were reviewed carefully to find
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compared by a third reviewer (Z.Q.L.) and the discrepancies
between searchers were discussed and solved with consensus. The
time period for literature searching was from the first available
article to April 1
th 2012. Publications were retrieved using terms
related to platinum drugs (‘‘platinum’’ or ‘‘cisplatin’’ or ‘‘carbo-
platin’’ or ‘‘oxaliplatin’’) in combination with keywords related to
genetic variation (‘‘polymorphism’’ or ‘‘SNP’’ or ‘‘single nucleotide
polymorphism’’ or ‘‘mutation’’ or ‘‘variation’’) and ‘‘lung cancer’’.
Publication selection criteria: Publications meeting the following
criteria were included: (a) patients with NSCLC; (b) trials had
platinum-based chemotherapy; (c) the data of response rate
stratified by polymorphisms could be obtained or derived from
the original article or corresponding author. Studies were excluded
if any of the following applies: (a) papers written in a language
other than English; (b) the data of response rate stratified by
polymorphisms could not be provided; (c) repeated publications,
abstracts, letters, or review articles.
Data extraction: Data were manually extracted independently
by two authors (J.Y.Y. and Q.H.), who were blind to each other,
using the same data recording form. After exaction, all results were
reviewed and compared by a third reviewer (Z.Q.L.) and the
discrepancies between extractors were discussed and solved with
consensus. When necessary, data of some studies were obtained
directly from corresponding authors. The following information of
each study was collected: first author’s name, publication year,
ethnicity (country), sample size, polymorphisms, dbSNP number
of investigated polymorphisms, genotyping methods, disease stage,
chemotherapeutic drugs, and the number of responders and non-
responders in different genotypes.
Data analysis: The patients were divided into two groups:
responders (including complete responders (CR) and partial
responders (PR)) and non-responders (including stable disease (SD)
andprogressivedisease(PD)).Alldatawereloadedintoandanalyzed
by the Cochrane Collaboration software (Review Manager 5, the
CochraneCollaboration,Oxford,UK).Thepooledoddsratio(OR)
and associated 95% confidence interval (CI) were calculated. The
significance of the pooled OR was determined using the Z test. The
heterogeneityofpublicationsineachmeta-analysiswasevaluatedby
I
2statisticalanalysis,whichdescribestheproportionoftotalvariation
acrossstudiesduetoheterogeneityratherthanchance.Asaguide,I
2
valuerangedfrom0to100%,andvaluesof25%,50%and75%were
considered as low, moderate and high heterogeneity respectively
[13]. To further evaluate the extent of heterogeneity between
publications, Cochran’s x
2 based Q statistic test was also employed
[14]. The threshold significance level of heterogeneity was set at
P=0.10. If P,0.10, the random-effect model using DerSimonian
andLairdmethodwasselectedtopooltheresults,yieldingwiderCIs
[15,16].Otherwise,thepooledORsandPvalueswerecalculatedby
fixed-effect model using the Mantel-Haenszel method [17]. To
control publication bias, the relationship between OR and SE (log
[OR])wasestimatedusingfunnelplot.Thesymmetryoffunnelplots
was visually inspected. To further evaluate publication bias, Begg’s
test [18] and Egger’s test [19] were also performed using Stata 12.0
software (StataCorp LP, College Station, USA). A P,0.05 was
considered statistically significant in all analyses, except for hetero-
geneity test.
Results
1. Literature Review, Characteristics of Studies and
Publication Bias
The contents of this meta-analysis were summarized in Table
S1. Our initial electronic search retrieved 1653 publications,
among which, 176 were review articles, 1084 were obviously not
relevant to this investigation, and 236 were in vitro studies.
Therefore, 157 studies were included in the next round of review.
After reading the full text of these articles, we found that 71
focused on other tumors, 25 didn’t provide enough information,
19 focused on disease prognosis, 4 focused on drug side effect, 13
were conference abstracts without sufficient data, and 1 was
duplicated publication. Finally, 24 publications met the inclusion
criteria with enough data to be extracted (Figure 1 and S7). These
publications included 11 polymorphisms in 8 genes (Table 1).
Visual inspection of the funnel plots of all meta-analysis revealed a
symmetrical inverted V shape (Figure 2). Begg’s test and Egger’s
test also didn’t suggest evidence of publication bias. Thus, there
was no publication bias for all meta-analysis in the present study.
The characteristics of these studies were summarized in Table 2.
2. Nucleotide Excision Repair (NER) Pathway
DNA repair was one of the most important pathways involved
in platinum response. Therefore, polymorphisms of genes in DNA
repair pathway may affect patients’ response to platinum
chemotherapy. There were four major DNA repair pathways:
nucleotide excision repair (NER), base excision repair (BER),
double-strand break repair (DSB) and mismatch repair (MMR)
[20]. NER was the major repair system for removal of platinum-
caused DNA lesions [20,21]. Thus it was closely related with
platinum response. Our meta-analysis contained 3 genes in NER
pathway: ERCC1, xeroderma pigmentosum group D (XPD) and
xeroderma pigmentosum group G (XPG).
2.1 ERCC1. The most extensively studied polymorphism was
ERCC1 C354T. Ten studies examined the association between
this polymorphism and platinum-based drug response in NSCLC
patients. We conducted a meta-analysis on these studies, which
included 1002 subjects (495 CC genotype and 507 CT+TT
genotype carriers). Because there was heterogeneity across the
studies (P=0.01, I
2=57%), we chose random-effect model.
Pooled data from these investigations showed 42.4% and 39.3%
overall response rate in CC genotype and CT+TT genotype
group, respectively. No significant relationship was detected
between ERCC1 C354T and drug response (OR=1.20, 95%
CI: 0.7521.93, P=0.44) (Figure 3A). We further analyzed their
relationship stratified by ethnic populations. The result showed
that ERCC1 C354T was not correlated with drug response in
either Asian or Caucasian population (Figure S1).
C8092A was another polymorphism of ERCC1 that was
included in this study [9,22]. Since heterogeneity was also
identified among the three studies (P=0.009, I
2=79%), ran-
dom-effect model was selected. Again, no significant association
between ERCC1 C8092A and drug response was detected
(OR=1.43, 95% CI: 0.4524.58, P=0.54) (Figure 3B).
2.2 XPD. Another intensively investigated gene in the NER
pathway was XPD. Two polymorphisms (G934A and A2251C)
were widely studied. Meta-analysis of G934A and A2251C
included 7 and 11 studies, respectively. No heterogeneity was
found across these studies (P=0.77, I
2=0% and P=0.79, I
2=0%
for G934A and A2251C, respectively), thus we chose fixed-effect
model. For XPD G934A, pooled data contained 562 patients.
Response rates for the GG genotype carriers and GA+AA
genotype carriers were 39.6% and 33.9%, respectively. However,
the OR (1.06) and 95% CI (0.7221.55) values indicated that there
was no significant correlation between this polymorphism and
platinum-based chemotherapy (P=0.77) (Figure 3C). In terms of
XPD A2251C, 11 studies included 1331 individuals in total. The
response rate for AA genotype was 32.9%, while that for AC+CC
genotype was 31.6%. No significant association was found
Platinum Chemotherapy Meta-Analysis
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Table 1. Polymorphisms involved in this study and the response rate in different alleles.
Genes Polymorphisms NCBI SNP ID Allele Responders Non-responders References
ERCC1 C354T rs11615 C 210 285 [6–8,22,59–64]
(Asn118Asn) T 199 308
C8092A rs3212986 C 85 87 [9,22,65]
A8 5 9 3
XPD G934A rs1799793 G 114 174 [7–9,59,63,66–68]
(Asp312Asn) A 93 181
A2251C rs13181 A 259 528 [7–9,59,63,65–70]
(Lys751Gln) C 172 372
XPG T138C rs1047768 C 13 20 [23,24]
(His46His) T 41 131
XRCC1 G1196A rs25487 G 60 110 [9,23,68,69]
(Arg399Gln) A 71 152
MDR1 C3435T rs1045642 C 49 46 [8,32,60,63,71]
(Ile1145Ile) T 88 141
G2677T/A rs2032582 G 31 22 [32,60,71]
(Ala893Ser/Thr) T/A 44 67
GSTP1 A313G rs1695 A 64 181 [9–11,72]
(Ile105Val) G 67 113
GSTM1 Deletion NR presence 31 63 [9,62]
deletion 38 40
RRM1 C-37A NR C 87 123 [8,36,63]
A6 5 9 2
NR: not reported.
doi:10.1371/journal.pone.0038150.t001
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CI: 0.8921.49, P=0.27) (Figure 3D). Analysis stratified by
different populations was further investigated, with no significant
correlation detected for polymorphism in either Asian or
Caucasian population (Figures S3 and S4). Taken together,
neither polymorphism of XPD was significantly related with
platinum-based chemotherapy in NSCLC patients.
2.3 XPG. Another genetic polymorphism in the XP family
involved in this study was XPG T138C. Sun et al. showed that it
was significantly associated with platinum-based chemotherapy
(P=0.047) [23] while, another study didn’t find significant
correlation between this SNP and chemotherapeutic drug
response (OR=2.57, 95% CI: 0.8627.66, P=0.083) [24].
T138C was a synonymous mutation. Our meta-analysis contained
these two contradictory investigations, and no heterogeneity was
found across these two studies (P=0.59, I
2=0%). As a result, no
significant correlation was found between this polymorphism and
drug response (OR=2.07, 95% CI: 0.9524.53, P=0.07)
(Figure 3E).
3. Other Pathways
Although NER was the most important pathway for platinum
drug resistance, other genetic polymorphisms were also widely
studied, including other DNA repair pathways, detoxification
system and drug transporters.
3.1 X-Ray Cross-Complementing Group 1
(XRCC1). Another extensively studied DNA repair gene is
XRCC1, which belongs to BER pathway. In this meta-analysis,
three publications investigated G1196A of XRCC1. No hetero-
geneity was found across the three studies (P=0.90, I
2=0%).
Thus fixed-effect model was selected. The pooled data showed that
no significant association was found between this polymorphism
and drug response (OR=1.21, 95% CI: 0.7821.87, P=0.39)
(Figure 4A).
3.2 Multidrug resistance 1 (MDR1). The decreased
accumulation of drug in the cell has been proved to be a common
mechanism of drug resistance [25]. There were two major causes
of reduced intracellular drug accumulation: decreased drug influx
and increased drug efflux. In terms of platinum resistance,
polymorphisms of MDR1 were extensively studied.
Five studies investigated MDR1 C3435T, including a total of
379 patients, the response rates in the CC and CT+TT genotype
group were 51.2% and 37.6%, respectively. No heterogeneity
across the studies was found (P=0.77, I
2=0%). We thus selected
fixed-effect model. The result showed that this polymorphism was
significantly correlated with drug response (OR=1.82, 95% CI:
1.1722.85, P=0.008) (Figure 5A). CC genotype carrier showed
significant increased drug response. Considering that ethnic
differences between populations may contribute to the drug
response and our included five studies comprise two different
ethnic populations, we further conducted separate analyses in
Asian and Caucasian population, respectively. It was interesting to
note that MDR1 C3435T was only significantly correlated with
platinum response in Asian population (P=0.02) (Figure 5B). No
association was detected in Caucasian population (P=0.19)
(Figure 5C).
Another MDR1 polymorphism involved in this meta-analysis
was G2677A/T. Heterogeneity test showed that fixed-effect model
should be selected (P=0.51, I
2=0%). It was interesting to found
that this SNP was also significantly associated with platinum
response (OR=2.61, 95%CI: 1.4424.74, P=0.002), patients with
GG genotype had better response to platinum based chemother-
apy (Figure 4B). Furthermore, it is noteworthy that all studied
included for this SNP were conducted in the Asian population.
Thus, taken together, MDR1 polymorphisms were correlated with
NSCLC patients’ platinum-based chemotherapy in Asian popu-
lation.
Figure 2. Funnel plots of SE (log [OR]) by the OR in meta-analysis. SE (log [OR]) is standard error of log [OR]. Each dot represents one article.
doi:10.1371/journal.pone.0038150.g002
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e381503.3 Glutathione S-transferase P1 (GSTP1). Once platinum
enters the cells, it could be conjugated by glutathione (GSH). The
formed complex reduces the toxicity of platinum and can be more
easily transported out of the cells. The conjugation is determined
by the cellular GSH level. Therefore, some GSH synthesis
enzymes are correlated with platinum response. One of the most
important enzymes is glutathione S-transferase (GST), which
includes several members such as GSTP1, GSTM1 and GSTT1.
GSTP1 A313G was the most widely studied polymorphism. We
included four publications and conducted a meta-analysis. These
studies included 425 patients. Response rates of the AA and
AG+GG genotype group were 26.1% and 37.2%, respectively.
Because heterogeneity was detected across these studies (P=0.03,
I
2=67%), we selected random-effect model. The result showed no
association between GSTP1 A313G and platinum-based chemo-
therapy (OR=0.61, 95% CI: 0.2921.28, P=0.19) (Figure 6A).
To avoid the additional heterogeneity introduced by different
Figure 3. Meta-analysis of association polymorphisms in NER DNA repair pathway genes and platinum-based chemotherapy in
NSCLC patients. No significant association was found for these polymorphisms.
doi:10.1371/journal.pone.0038150.g003
Figure 4. Meta-analysis of association between other pathways gene polymorphisms and platinum-based chemotherapy in NSCLC
patients. No significant association was found for XRCC1 G1196A (A), GSTM1 (C) and RRM C-37A (D), while significant correlation was identified for
MDR1 G2677A/T (P=0.002) (B).
doi:10.1371/journal.pone.0038150.g004
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PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e38150ethnic population, we further analyzed the correlation stratified by
different populations. As showed in Figure 6 B and C, GSTP1
A313G was only significantly associated with drug response in
Asian population.
One deletion polymorphism of GSTM1 was also investigated in
this study, heterogeneity was detected across involved two studies
(P=0.04, I
2=75%), random-effect model was used to evaluate
correlation between GSTM1 polymorphism and drug response.
However, no significant association was detected (OR=0.54, 95%
CI: 0.1322.18, P=0.39) (Figure 4C).
3.4 Ribonucleotide reductase M1 (RRM1). The last
enrolled gene was RRM1. Three studies investigated the
polymorphism of C-37A. No heterogeneity was detected across
the studies (P=0.62, I
2=0%). Thus fixed-effect model was
selected. We didn’t find significant correlation between this SNP
and drug response (OR=1.04, 95% CI: 0.6821.58, P=0.87)
(Figure 4D).
Discussion
In this study, we investigated the phamacogenetics of platinum-
based chemotherapy in NSCLC patients. We conducted meta-
analysis for 11 polymorphisms in 8 genes. The results showed that
MDR1 C3435T, G2677A/T and GSTP1 A313G were signifi-
cantly correlated with platinum-based chemotherapy in the Asian
NSCLC patients.
Platinum is an effective chemotherapeutic drug for lung cancer
patients. However, the mechanisms for individual difference on
drug response remain unknown. Gene polymorphisms have been
proved to play an important role in the drug therapeutic efficacy
[5,25–27]. Therefore, researchers focused on the polymorphisms
of the genes in the platinum pathways [12]. In the present study, it
is interesting that two polymorphisms of MDR1 were significantly
correlated with platinum response. MDR1 encodes P-glycoprotein
(P-gp), which is responsible for transporting a broad spectrum of
drugs out of cells [28]. It was widely reported to be implicated in
platinum resistance due to its activity of drug efflux [29]. Thus it is
not surprising that MDR1 polymorphisms were associated with
platinum response. However, the mechanisms of their correlation
remain unclear. One proposal is that these polymorphisms affect
P-gp protein expression or function which, in turn, alter drug
efflux activity. A number of publications reported the association
between MDR1 C3435T and G2677A/T and P-gp expression or
function. The mutated MDR1 had altered P-gp expression level or
aberrant protein function [30,31]. It was previously reported that
C3435T and G2677A/T were in linkage disequilibrium (LD) with
each other [32]. Thus their haplotype may also have significant
contribution to platinum response. However, existing literatures
do not provide enough data for a meta-analysis for this hypothesis.
Figure 5. Meta-analysis of association between MDR1 C3435T and platinum-based chemotherapy in overall (A), Asian (B) and
Caucasian (C) NSCLC patients. Significant association was identified in overall (P=0.008) and Asian (P=0.02) populations.
doi:10.1371/journal.pone.0038150.g005
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PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e38150Therefore, their correlation awaits further investigations. Another
polymorphism found to be significantly correlated with drug
response was GSTP1 A313G, which is a non-synonymous SNP
located in exon 5 [33]. GSTs are phase II metabolic enzymes
involved in the platinum detoxification mediated by glutathione
(GSH) conjugation [34]. GSTP1 is one of the major isoforms of
GST and its activity level is associated with platinum detoxifica-
tion and subsequent drug response. Previous study showed that
GSTP1 A313G resulted in reduced glutathione conjugating ability
[33]. Thus, patients harboring this polymorphism may have
decreased platinum detoxification capacity, which is consistent
with our result that mutated genotype carriers were more sensitive
to platinum-based chemotherapy.
Except for drug transporters and detoxification, DNA repair
was also one of the classical platinum resistance mechanisms [34],
We proposed that genetic polymorphisms in DNA repair pathways
were correlated with drug response prior to this study. However,
we failed to find the significant correlation between genetic
polymorphisms in any DNA repair pathway and platinum
chemotherapy response in this study. To further verify this result,
we examined more DNA repair pathway polymorphisms, which
were not included in this study because they didn’t meet our
including criteria. Among these, ERCC1 T262G [22], hMSH2
IVS12-6T.C [35], RRM1 C-524T [36], XPA A23G [24] and
XRCC1 T194C [23] were claimed to be significantly associated
with drug response by other authors. However, after careful
examination on these studies, we found several problems in these
studies. For example, adjusted OR values were not calculated for
RRM1 C-524T. Besides, the results of hMSH2 IVS12-6T.C and
XRCC1 T194C were inconsistent between different genotypes.
We did not find similar problems in the analyses of ERCC1
T262G and XPA A23G. However, due to the small sample size,
we think these results need to be further validated. Taken both our
and these studies together, the association between genetic
polymorphisms in DNA repair pathway and platinum-based
chemotherapy in NSCLC is not supported by experimental
evidence.
Considering the importance of these genes in platinum
resistance, especially for NER DNA repair pathway genes, it is
surprising that no correlation was detected. We think one
possibility is that cancer genetics is different from somatic genetics.
Although a number of studies showed that polymorphisms in these
genes affect their expression or function [37,38], they may have no
effect on cancer patients’ chemotherapeutic efficiency. We
understand that many other cancer genetic factors also affect the
therapeutic efficiency of platinum. Thus, the polymorphisms in
DNA repair pathway genes may not play a central role in
platinum drug response in NSCLC. This is supported by a large
sample size study conducted by Shiraishi et al [39], who genotyped
30 SNPs in 27 DNA repair genes in 640 NSCLC patients. Some
of the polymorphisms were also investigated in the present study
such as XPD A2251C and XRCC1 G1196A. Their results were in
Figure 6. Meta-analysis of association between GSTP1 A313G and platinum-based chemotherapy in overall (A), Asian (B) and
Caucasian (C) NSCLC patients. Significant association was identified in the Asian (P=0.0002) populations.
doi:10.1371/journal.pone.0038150.g006
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PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e38150agreement with ours in that, most of polymorphisms in the DNA
repair pathway genes were not significantly involved in platinum
drug response. Our results are also supported by several recent
large genome wide association studies (GWAS) in NSCLC [40–
42]. Wu et al. conducted a GWAS (including 307,260 SNPs) in a
total of 1062 NSCLC patients, they identified that the rs1878022
in the chemokine-like receptor 1 (CMKLR1) was statistically
associated with poor overall survival [41]. No polymorphisms in
the DNA repair pathway genes were identified. Another GWAS
study performed by Yang group also didn’t identify the correlation
between DNA repair gene polymorphisms and patients overall
survival in NSCLC [42], either. They explored 894 SNPs in 70
genes in four pathways related to chemotherapy drug actions,
including GSH, DNA repair, cell cycle and EGFR pathways.
However, this 1076 patients study concluded that only genetic
variations in EGFR and glutathione pathways were associated
with overall survival in NSCLC patients receiving platinum based
chemotherapy. Although the endpoints in these studies were
overall survival, considering the close association between drug
response and survival, they may also provide some clues for the
correlation between these SNPs and drug response. Taken
together, compared with DNA repair pathway genetic polymor-
phisms, other gene polymorphisms may have more contribution to
chemotherapy response in NSCLC patients receiving platinum-
based treatment.
Lung cancer is a heterogeneous disease. Thus pathological and
ethnic difference may affect drug response. To clarify this concern,
we analyzed the correlation between genetic polymorphisms and
drug response stratified by different ethnic populations (Figure 5, 6
and S1, S2, S3, S4, S5, and S6). Although most of the separately
analyzed results were consistent with overall population, two
polymorphisms (MDR1 C3435T and GSTP1 A313G) showed
ethnic difference. Both polymorphisms were only significantly
associated with drug response in Asian population, not in
Caucasian population (Figure 5 and 6). This result indicates that
the outcomes of platinum-based chemotherapy differ between
Asian and Caucasian population. Thus, ethnic factor should be
considered if personalized chemotherapy treatment is conducted
in the future.
Pathology is another factor to be considered when pooled data
was analyzed, because NSCLC includes adenocarcinoma and
squamous cell carcinoma. Although both types of tumor are
treated with the same regimen, the outcomes may be completely
different. However, studies included in this meta-analysis didn’t
provide the data of response rate stratified by both polymorphisms
and pathological types. Thus it is impossible to do the meta-
analysis separately on adenocarcinoma and squamous cell
carcinoma based on existing studies. This is one of the limitations
of our study. To address this issue, future studies are needed when
enough data are available.
We also identified some flaws in existing studies. One common
flaw is that the authors didn’t perform comprehensive analysis. As
our result indicated, a single polymorphism has little contribution
to chemotherapy efficacy. Thus comprehensive analysis was
needed. One restriction for the past comprehensive study is
shortage of high-throughput genotyping methods. With the
advancement of technology, more and more methods have been
developed for performing high-throughput genotyping, which can
be used in the future study. For example, in our included studies,
one group used 3D polyacrylamide gel-based DNA microarray to
determine genotypes [10,23,24,35]. This is a powerful high-
throughput genotyping assay, which is frequently utilized by this
group. As gene sequencing technology develops rapidly, another
available method is genome-wide approach. One group identified
some variants that were related with platinum response using this
method [43–46]. However, all these studies are in vitro investiga-
tions and the results need to be verified in the patients. On the
other hand, GWAS have been successfully used in disease
susceptibility and pharmacogenetic research [47–50]. Thus, we
believe GWAS is a powerful tool to investigate the pharmacoge-
netics of platinum-based chemotherapy in the future. Another
problem is inadequate sample size. The sample sizes of involved
studies were from 33 to 355, and none of these studies did a
sample size calculation. In some situation, especially for the low
frequency polymorphisms, small sample size cannot generate solid
conclusion. Furthermore, as described previously, some studies
didn’t calculate adjusted OR [36,51]. They just used x
2 test to
assess the distribution of different genotypes in responders and
non-responders. Thus, these studies can’t exclude the effect of age,
sex, smoking habit, tumor histology, and tumor stages. To make
the result more reliable, future studies should avoid these pitfalls.
The cellular process of platinum is complicated, which includes
a lot of pathways. However, existing studies didn’t cover all
platinum pathways. Therefore, some most important polymor-
phisms affecting platinum chemotherapy may still be elusive. For
instance, compared with efflux, drug influx is also crucial for
platinum accumulation in the tumor cells. Copper transporter-1
(CTR1) and ATPases ATP7 have a substantial role in platinum
influx [52–54]. However, no polymorphisms of these genes were
investigated. Other important pathways that didn’t attract
attention include DNA damage signal transduction pathways.
These pathways are, but not limited to, AKT, c-ABL, p53,
MAPK/JNK/ERK and p38 MAPK [55]. We didn’t find
publications investigating polymorphisms of genes in these
pathways. Therefore, we propose that another possible direction
in the future is to investigate genes in these pathways.
Prior to this study, another two groups performed meta-analysis
to detect the correlation of ERCC1 and MDR1 polymorphisms
and platinum-based chemotherapies in advanced NSCLC [56,57].
Our results are in agreement with these two studies. However, a
study conducted by Wei et al. had different results. They
investigated the association between ERCC1 and XPD polymor-
phisms and platinum-based chemotherapy in advanced NSCLC
patients [58]. They studied ERCC1 C354T, XPD G934A and
A2251C, and found that ERCC1 C354T was significantly
correlated with drug response in patients treated with platinum-
based chemotherapy. Apparently, their result is inconsistent with
our study. We think that the discrepancy comes from the
difference in enrolled studies. Our meta-analysis included six
more studies, five of which are published after Wei’s meta-analysis.
In the other one, data were obtained directly from the author.
Besides, our investigation didn’t include two studies, which were in
Wei’s investigation. One study was not published in English, and
the other had errors in genotype classification. As a result, our
meta-analysis included 1002 patients, while Wei’s study included
556 patients. Therefore, the difference in patients pool possibly
caused inconsistency in results.
In conclusion, we identified that MDR1 C3435T, G2677A/T
and GSTP1 A313G were significantly correlated with platinum-
based chemotherapy in Asian NSCLC patients. These polymor-
phisms should be considered for personalized chemotherapy
treatment for NSCLC patients in Asian population in the future.
Supporting Information
Figure S1 Meta-analysis of association between ERCC1 C354T
and platinum-based chemotherapy in NSCLC patients stratified
Platinum Chemotherapy Meta-Analysis
PLoS ONE | www.plosone.org 10 June 2012 | Volume 7 | Issue 6 | e38150by ethnic population. No significant association was found in
either Asian (A) or Caucasian (B) population.
(TIF)
Figure S2 Meta-analysis of association between ERCC1
C8092A and platinum-based chemotherapy in Caucasian NSCLC
patients. No significant association was identified.
(TIF)
Figure S3 Meta-analysis of association between XPD G934A
and platinum-based chemotherapy in Caucasian NSCLC patients.
No significant association was detected.
(TIF)
Figure S4 Meta-analysis of association between XPD A2251C
and platinum-based chemotherapy in NSCLC patients stratified
by ethnic population. No significant association was found in
either Asian (A) or Caucasian (B) populations.
(TIF)
Figure S5 Meta-analysis of association between XRCC1
G1196A and platinum-based chemotherapy in Caucasian NSCLC
patients. No significant association was found.
(TIF)
Figure S6 Meta-analysis of association between RRM1 C-37A
and platinum-based chemotherapy in Caucasian NSCLC patients.
No significant association was detected.
(TIF)
Figure S7 PRISMA flow diagram
(DOC)
Table S1 PRISMA checklist
(DOC)
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